The call highlighted significant achievements, including an early FDA approval and successful product launch, strong initial market penetration, and financial strength. Despite increased R&D and SG&A expenses, the positive momentum and strategic execution in the commercial launch phase suggest a positive outlook.

Company Guidance -

Q3 2025

During the Verastem Oncology Second Quarter 2025 Financial Results Conference Call, the company highlighted several key metrics and milestones. They reported $2.1 million in net product revenue from the AVMAPKI FAKZYNJA CO-PACK within just six weeks of its commercial launch, following its accelerated FDA approval nearly two months ahead of schedule. The approval marked the first FDA-approved therapy for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), a significant area of unmet medical need. The company has secured coverage from major U.S. insurers, representing over 80% of lives, and has seen prescriptions for patients experiencing their first recurrence and those with advanced disease who have undergone multiple lines of therapy. Verastem also raised $75 million through a private placement, ending the quarter with $164.3 million in cash and equivalents, providing a financial runway into the second half of 2026. Their strategic focus includes further advancing key clinical programs and maintaining momentum in the market through targeted engagement with healthcare providers and patient support initiatives.

FDA Approval and Successful Launch

Secured FDA approval for AVMAPKI FAKZYNJA CO-PACK nearly 2 months ahead of schedule, marking a major milestone with the first-ever treatment for KRAS-mutated recurrent LGSOC. Successfully launched with $2.1 million in net product revenue within 6 weeks.

Strong Initial Market Penetration

93% of the top 100 parent organizations and 84% of the top 100 office locations contacted. High engagement and prescription uptake from both academic and community practices.

Financial Strength

Strengthened financial position with a $75 million private placement, ending the quarter with $164.3 million in cash and equivalents, providing a cash runway into the second half of 2026.

Positive Patient and Physician Feedback

High enthusiasm from physicians and positive feedback regarding product profile. Patients receiving comprehensive support through Verastem's Care support program.

Verastem (VSTM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VSTM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.59 / -	-0.6	―	―	―
Aug 07, 2025	2025 (Q2)	-0.73 / -0.39	-0.31	-25.81% (-0.08)	―
May 13, 2025	2025 (Q1)	-0.70 / -0.96	-1.26	23.81% (+0.30)	―	―
Mar 20, 2025	2024 (Q4)	-0.83 / -1.33	-1.02	-30.39% (-0.31)	―	―
Nov 06, 2024	2024 (Q3)	-0.74 / -0.60	-0.75	20.00% (+0.15)	―	―
Aug 08, 2024	2024 (Q2)	-0.96 / -0.31	-1.37	77.37% (+1.06)	―	―
May 09, 2024	2024 (Q1)	-1.03 / -1.26	-0.96	-31.25% (-0.30)	―	―
Mar 14, 2024	2023 (Q4)	-0.61 / -1.02	-0.96	-6.25% (-0.06)	―	―
Nov 08, 2023	2023 (Q3)	-0.84 / -0.75	-1.08	30.56% (+0.33)	―	―
Aug 08, 2023	2023 (Q2)	-1.04 / -1.37	-1.44	4.86% (+0.07)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VSTM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.62	$6.74	+19.93%
May 13, 2025	$7.46	$7.13	-4.42%
Mar 20, 2025	$6.82	$6.65	-2.49%
Nov 06, 2024	$3.87	$3.60	-6.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Verastem (VSTM) report earnings?

Verastem (VSTM) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Verastem (VSTM) earnings time?

Verastem (VSTM) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VSTM EPS forecast?

VSTM EPS forecast for the fiscal quarter 2025 (Q3) is -0.59.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing